Table 2 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE + MPA trial
CEE + MPA trial | ||||||
|---|---|---|---|---|---|---|
Placebo | Active treatment | |||||
Cases | Controls | P-value* | Cases | Controls | P-value* | |
Estradiol (pg/ml) | ||||||
Baseline | 11.97 (4.96, 28.84) | 10.05 (4.36, 23.17) | 0.001 | 10.90 (4.83, 24.59) | 10.89 (4.19, 28.34) | 0.99 |
Year 1 | 10.12 (3.56, 28.71) | 8.46 (2.86, 25.02) | 0.008 | 22.30 (7.88, 63.06) | 20.78 (6.02, 71.72) | 0.28 |
Bioavailable estradiol (pg/ml) | ||||||
Baseline | 8.02 (2.89, 22.25) | 6.47 (2.49, 16.85) | 0.001 | 7.10 (2.71, 18.60) | 7.00 (2.31, 21.16) | 0.82 |
Year 1 | 6.75 (2.16, 21.06) | 5.35 (1.52, 18.76) | 0.002 | 9.95 (3.75, 26.38) | 9.98 (3.14, 31.71) | 0.96 |
Estrone (pg/ml) | ||||||
Baseline | 41.81 (17.36, 95.94) | 35.20 (14.99, 82.68) | 0.007 | 36.95 (16.06, 85.03) | 36.37 (15.79, 83.74) | 0.74 |
Year 1 | 37.68 (13.99, 101.49) | 34.39 (13.78, 85.81) | 0.14 | 117.48 (30.97, 445.66) | 103.96 (23.00, 469.86) | 0.14 |
Estrone sulfate (ng/ml) baseline | 0.84 | 0.79 | 0.26 | 0.82 | 0.80 | 0.65 |
(0.37, 1.91) | (0.33, 1.88) | (0.33, 2.08) | (0.29, 2.18) | |||
Year 1 | 0.75 (0.34, 1.67) | 0.69 (0.30, 1.59) | 0.17 | 1.88 (0.61, 5.81) | 1.77 (0.51, 6.14) | 0.37 |
SHBG (Nmol/L) | ||||||
Baseline | 36.93 (15.05, 90.63) | 41.94 (17.28, 101.80) | 0.02 | 40.49 (14.99, 109.42) | 39.81 (14.63, 108.31) | 0.76 |
Year 1 | 37.37 (14.22, 98.23) | 41.86 (16.51, 106.11) | 0.06 | 95.46 (31.96, 285.11) | 90.07 (30.96, 262.06) | 0.35 |